Intech Investment Management LLC Invests $172,000 in Aura Biosciences, Inc. (NASDAQ:AURA)

Intech Investment Management LLC bought a new stake in Aura Biosciences, Inc. (NASDAQ:AURA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,926 shares of the company’s stock, valued at approximately $172,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AURA. China Universal Asset Management Co. Ltd. bought a new stake in Aura Biosciences in the 4th quarter valued at $87,000. AlphaQuest LLC bought a new stake in Aura Biosciences in the fourth quarter valued at about $136,000. JPMorgan Chase & Co. raised its position in Aura Biosciences by 107.5% in the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock worth $477,000 after purchasing an additional 27,718 shares in the last quarter. Barclays PLC lifted its stake in Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in Aura Biosciences during the third quarter valued at approximately $1,037,000. 96.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 23,045 shares of company stock valued at $177,242 over the last three months. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $5.94 on Friday. The business’s fifty day moving average is $7.57 and its two-hundred day moving average is $8.62. The firm has a market cap of $296.71 million, a P/E ratio of -3.43 and a beta of 0.30. Aura Biosciences, Inc. has a 52 week low of $5.77 and a 52 week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, equities research analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

AURA has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Monday. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.